An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with...
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer
About this item
Full title
Author / Creator
Necchi, Andrea , Lo Vullo, Salvatore , Mariani, Luigi , Raggi, Daniele , Giannatempo, Patrizia , Calareso, Giuseppina , Togliardi, Elena , Crippa, Flavio , Di Genova, Nicola , Perrone, Federica , Colecchia, Maurizio , Paolini, Biagio , Pelosi, Giuseppe , Nicolai, Nicola , Procopio, Giuseppe , Salvioni, Roberto and De Braud, Filippo G.
Publisher
New York: Springer US
Journal title
Language
English
Formats
Publication information
Publisher
New York: Springer US
Subjects
More information
Scope and Contents
Contents
Summary
Background
Progress in developing effective salvage therapies for UC is warranted. Alisertib is an orally available, selective inhibitor of the aurora kinase A.
Methods
A single-group, phase 2 trial was conducted with alisertib 50 mg orally BID for 7 days, with 14d rest until disease progression (PD) (NCT02109328). The primary e...
Alternative Titles
Full title
An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer
Authors, Artists and Contributors
Author / Creator
Lo Vullo, Salvatore
Mariani, Luigi
Raggi, Daniele
Giannatempo, Patrizia
Calareso, Giuseppina
Togliardi, Elena
Crippa, Flavio
Di Genova, Nicola
Perrone, Federica
Colecchia, Maurizio
Paolini, Biagio
Pelosi, Giuseppe
Nicolai, Nicola
Procopio, Giuseppe
Salvioni, Roberto
De Braud, Filippo G.
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1772050223
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1772050223
Other Identifiers
ISSN
0167-6997
E-ISSN
1573-0646
DOI
10.1007/s10637-016-0328-9
